Northeast Financial Consultants’s Korro Bio KRRO Stock Holding History

Northeast Financial Consultants’s Portfolio KRRO Stock Details KRRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-857	Closed	-$14.8K	–	292
2023 Q2	$14.8K	Sell	857 -60	-7%	-$1.16K	﹤0.01%	287
2023 Q1	$23.1K	Hold	917	–	–	﹤0.01%	313
2022 Q4	$176K	Hold	917	–	–	0.01%	306
2022 Q3	$82K	Hold	917	–	–	0.01%	326
2022 Q2	$69K	Hold	917	–	–	﹤0.01%	321
2022 Q1	$97K	Buy	917 +600	+189%	+$115K	0.01%	380
2021 Q4	$81K	Sell	317 -510	-62%	-$155K	﹤0.01%	353
2021 Q3	$292K	Hold	827	–	–	0.02%	287
2021 Q2	$412K	Buy	827 +117	+16%	+$57.1K	0.03%	240
2021 Q1	$337K	Buy	710 +596	+523%	+$1.16M	0.03%	257
2020 Q4	$201K	Buy	+114	New	+$150K	0.02%	307

Other funds holding KRRO

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northeast Financial Consultants's KRRO Position: Q3 2023 in Review

Northeast Financial Consultants sold out of Korro Bio (KRRO) in Q3 2023, closing a stake of 857 shares — an estimated $14.8K sold.

Northeast Financial Consultants first reported a position in KRRO in Q4 2020 and held it in 11 quarters. The position peaked at $412K in Q2 2021. 41 funds tracked by Wall St. Rank hold KRRO as of Q3 2023.

Northeast Financial Consultants reported no remaining Korro Bio position as of Q3 2023 after selling out during the quarter.
Northeast Financial Consultants sold 857 Korro Bio shares in Q3 2023, an estimated $14.8K.
Northeast Financial Consultants first reported a position in Korro Bio in Q4 2020 and held it in 11 quarters.
Northeast Financial Consultants's Korro Bio position peaked at $412K in Q2 2021.
41 funds tracked by Wall St. Rank held Korro Bio as of Q3 2023.

Based on Northeast Financial Consultants's 13F filing for Q3 2023, filed 14 Nov 2023.